UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 74

Sortiert nach

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

The New England journal of medicine, 2019-11, Vol.381 (21), p.2020-2031

2019

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2021-03, Vol.384 (9), p.829-841

2021

Link zum Volltext

Verfügbarkeit prüfen

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Journal of thoracic oncology, 2022-02, Vol.17 (2), p.289-308

2022

Link zum Volltext

Verfügbarkeit prüfen

Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions

International journal of molecular sciences, 2016-11, Vol.17 (11), p.1876-1876

2016

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9500-9500

2020

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9501-9501

2020

Link zum Volltext

Verfügbarkeit prüfen

Pork for pilgrims: livestock breeding and meat consumption at medieval Banganarti, Nubia

Antiquity, 2020-02, Vol.94 (373), p.164-178

2020

Link zum Volltext

Verfügbarkeit prüfen

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry

European urology open science (Online), 2022-11, Vol.45, p.12-22

2022

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

The Lancet (British edition), 2020-12, Vol.396 (10265), p.1817-1828

2020

Link zum Volltext

Verfügbarkeit prüfen

Verbal fluency in breast cancer patients treated with chemotherapy

Breast cancer (Tokyo, Japan), 2017-05, Vol.24 (3), p.376-383

2017

Link zum Volltext

Verfügbarkeit prüfen

A systemic literature review of neuroimaging studies in women with breast cancer treated with adjuvant chemotherapy

Contemporary oncology (Poznań, Poland), 2017-01, Vol.21 (1), p.6-15

2017

Link zum Volltext

Verfügbarkeit prüfen

Banganarti and Selib in 2011/2012 and 2013

Polish archaeology in the Mediterranean, 2016-02, Vol.XXIV (1), p.369-388

Żurawski, Bogdan

2016

Link zum Volltext

Verfügbarkeit prüfen

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

The New England journal of medicine, 2023-05, Vol.388 (19), p.1767-1778

2023

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

The Lancet (British edition), 2023-03, Vol.401 (10379), p.821-832

2023

Link zum Volltext

Verfügbarkeit prüfen

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

Journal of thoracic oncology, 2023-02, Vol.18 (2), p.204-222

2023

Link zum Volltext

Verfügbarkeit prüfen

KRAS and BRAF Mutation Analysis in Colorectal Adenocarcinoma Specimens with a Low Percentage of Tumor Cells

Molecular diagnosis & therapy, 2013-06, Vol.17 (3), p.193-203

2013

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness analysis of treatment of patients with colorectal cancer with FOLFOX4 and XELOX regimens

Nowotwory, 2017-06, Vol.66 (6), p.470-476

2017

Link zum Volltext

Verfügbarkeit prüfen

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

The New England journal of medicine, 2023-11, Vol.389 (22), p.2039-2051

2023

Link zum Volltext

Verfügbarkeit prüfen

Whole BRCA1/2 exome screening in breast cancer tissue: Preliminary study on 45 patients negative in preventive screening analysis in Poland which cover the most common mutations in BRCA1/2 tested in blood

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e13615-e13615

2018

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): results from a double-blind, randomised, phase 3 trial

The Lancet (British edition), 2023-02, Vol.401 (10379), p.821-832

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(74)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Oncology
(23)
Humans
(20)
Art And Archaeology
(15)
Ancient Civilizations Of The Near East
(14)
Archaeology
(13)
Sudan
(13)
Adult
(11)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Female
(11)
Middle Aged
(10)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(9)
Immunotherapy
(9)
Cancer Therapies
(8)
Chemotherapy
(8)
Male
(8)
Metastasis
(8)
Mutation
(8)
Aged
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA

Pork for pilgrims: livestock breeding and meat consumption at medieval Banganarti, Nubia

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Verbal fluency in breast cancer patients treated with chemotherapy

A systemic literature review of neuroimaging studies in women with breast cancer treated with adjuvant chemotherapy

Banganarti and Selib in 2011/2012 and 2013

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

KRAS and BRAF Mutation Analysis in Colorectal Adenocarcinoma Specimens with a Low Percentage of Tumor Cells

Cost-effectiveness analysis of treatment of patients with colorectal cancer with FOLFOX4 and XELOX regimens

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

Whole BRCA1/2 exome screening in breast cancer tissue: Preliminary study on 45 patients negative in preventive screening analysis in Poland which cover the most common mutations in BRCA1/2 tested in blood

Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): results from a double-blind, randomised, phase 3 trial

Suchergebnisse filtern